Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2012

View Archived Issues

Biokine Therapeutics drug receives orphan drug status for use in stem cell mobilization

New model of abdominal wall allotransplantation developed in China

Novavax reports on clinical programs for VLP vaccine candidates

Two new photosensitizers show promise for use in cancer

Avagacestat evaluated in Asian subjects

Purdue Pharma discloses novel sodium channel blockers

Scientists at Avidin present new anticancer agents

Protalex reports on PRTX-100 trial in RA

SuppreMol enters agreement to develop SM-401 for rheumatoid arthritis

Novel antibacterial vaccines patented by Novartis

U.S. study uncovers basis for LOAD locus heterogeneity in the Amish

Proteostasis Therapeutics expands collaboration with Scripps Research Institute

IRM designs new farnesoid X receptor agonists

Pfizer files application for Prevenar 13

Biodel awarded NIH grant to develop concentrated ultrarapid-acting insulin

Novel agents for migraine divulged

Group at Abbott prepares new IL-1 alpha-binding proteins

Otsuka receives FDA complete response letter regarding new aripiprazole formulation

U.S. researchers report novel glucagon receptor agonists

Alimera obtains marketing approval in Germany for Iluvien

Kyowa Hakko Kirin set to launch Apokyn in Japan

FDA approves Vascepa to reduce triglyceride levels in adults with severe hypertriglyceridemia

Eisai obtains European approval for perampanel

FDA advisory committee recommends approval of Genentech drug for DME

Quattrovac approved in Japan

Luitpold receives FDA complete response letter for Injectafer

FDA approves novel formulation of prednisone for rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...